Search results for "Lymphocytic"

showing 10 items of 167 documents

Chromosome 5 abnormalities in acute lymphoblastic leukemia

1991

Abstract We report two cases of acute lymphoblastic leukemia with involvement of chromosome 5. One of them showed a del(5)(q13q33) in a 5-year-old boy who had previously received antineoplastic chemotherapy for an L1-ALL that had been diagnosed nine months before. The other one showed a t(5;7)(q12–13;q36) together with a t(8;14)(q24;q32) and a der(1) in a 66-year-old man with an L3-ALL. Both chromosome 5 aberrations are interpreted as evolutionary events. In the first case, it was secondary to chemotherapy treatment; in the second, an evolutionary chromosome rearrangement, considering the translocation between chromosomes 8 and 14 as the primary cytogenetic event.

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentLymphoblastic LeukemiaChromosome DisordersChromosomal translocationChromosomal rearrangementBiologyAcute lymphocytic leukemiaAntineoplastic chemotherapyGeneticsmedicineHumansMolecular BiologyChromosome AberrationsChemotherapyCytogeneticsChromosomePrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseChromosome BandingChild PreschoolKaryotypingImmunologyCancer researchChromosomes Human Pair 5Cancer Genetics and Cytogenetics
researchProduct

The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia.

2011

AbstractIdentification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detection/readout complexities, abnormality of κ and λ serum-free light chain ratio [sFLC (κ/λ)] was proposed as a straightforward prognosticator in CLL. By analyzing 449 therapy-naive patients, we show that an abnormal sFLC(κ/λ), along with CD38, ZAP-70, IGHV mutations, cytogenetics and stage, independently predicts treatment-free survival (TFS) but becomes prognostically irrelevant if the cumulative amount of clonal and nonclonal FLCs [sFLC(κ + λ)], a variable associated …

MaleChronic lymphocytic leukemiaMICROENVIRONMENTPROGRESSIONCD38GUIDELINESBiochemistryCohort StudiesBone MarrowLYMPHOMAMedicineAged 80 and overHematologyMiddle AgedPrognosisLeukemiaB-CELLSMonoclonalDisease ProgressionBiological MarkersFemaleIGHV@AlgorithmsAdultmedicine.medical_specialtyDISORDERSB-CELLS; CLINICAL-SIGNIFICANCE; CD38 EXPRESSION; LYMPHOMA; CLL; MICROENVIRONMENT; PROGRESSION; GUIDELINES; DISORDERS; DIAGNOSISImmunologyImmunoglobulin light chainDIAGNOSISImmunoglobulin kappa-ChainsImmunoglobulin lambda-ChainsHumansCLINICAL-SIGNIFICANCESurvival analysisAgedbusiness.industryCytogeneticsCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisCD38 EXPRESSIONImmunologyCancer researchImmunoglobulin Light ChainsLymph NodesbusinessSettore MED/15 - Malattie del SangueBiomarkersCLLFollow-Up Studies
researchProduct

Increased Oxidative Damage Associated with Unfavorable Cytogenetic Subgroups in Chronic Lymphocytic Leukemia

2014

Oxidative stress contributes to genomic instability in chronic lymphocytic leukemia (CLL), but its relationship with the acquisition of specific chromosomal abnormalities is unknown. We recruited 55 untreated CLL patients and assessed 8-oxo-2′-deoxyguanosine (8-oxo-dG), glutathione, and malondialdehyde (MDA) levels, and we compared them among the cytogenetic subgroups established using fluorescence in situ hybridization (FISH). Significant increases in 8-oxo-dG and/or MDA were observed in patients with unfavorable cytogenetic aberrations (17p and 11q deletions) compared to the 13q deletion group.TP53deletion patients exhibited a diminished DNA repair efficiency. Finally, cases with normal F…

MaleGenome instabilityArticle SubjectDNA RepairDNA damageDNA repairChronic lymphocytic leukemialcsh:MedicineBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyCohort Studieschemistry.chemical_compoundMalondialdehydemedicineHumansLymphocytesIn Situ Hybridization FluorescenceAgedAged 80 and overChromosome AberrationsGeneral Immunology and Microbiologymedicine.diagnostic_testlcsh:RDeoxyguanosineGeneral MedicineGlutathioneMiddle AgedMalondialdehydemedicine.diseaseGlutathioneLeukemia Lymphocytic Chronic B-CellOxidative Stresschemistry8-Hydroxy-2'-DeoxyguanosineImmunologyFemaleLipid PeroxidationReactive Oxygen SpeciesGene DeletionOxidative stressDNA DamageResearch ArticleFluorescence in situ hybridizationBioMed Research International
researchProduct

IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins

2004

Abstract We recently proposed that Th1 and Th2 cytokines exert opposite effects on the pathogenesis and clinical outcome of organ-specific autoimmunity by altering the expression of genes involved in target cell survival. Because a Th2 response against tumors is associated with poor prognosis, we investigated the ability of IL-4 to protect tumor cells from death receptor- and chemotherapy-induced apoptosis. We found that IL-4 treatment significantly reduced CD95 (Fas/APO-1)- and chemotherapeutic drug-induced apoptosis in prostate, breast, and bladder tumor cell lines. Analysis of antiapoptotic protein expression revealed that IL-4 stimulation resulted in up-regulation of cellular (c) FLIP/F…

MaleINFILTRATING LYMPHOCYTESCell SurvivalImmunologyCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsCARCINOMA-CELLSBiologySIGNALING PATHWAYSDownregulation and upregulationCell Line TumorImmunology and AllergyHumansfas ReceptorNON-HODGKINS-LYMPHOMACANCER PATIENTSReceptorBCL-2 PROTEINInterleukin 4EtoposideIL-4 apoptosis cancer stem cellsSettore MED/04 - Patologia GeneraleCHRONIC LYMPHOCYTIC-LEUKEMIAIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalProstatic NeoplasmsFas receptorRecombinant ProteinsCell biologyUp-RegulationProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureFlipCancer researchT-CELLSCamptothecinFemaleInterleukin-4FLICE-INHIBITORY PROTEINSignal transductionCarrier ProteinsRENAL-CELL
researchProduct

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk C…

2017

Patients with chronic lymphocytic leukemia with del(17p) or del(11q) have poor long-term prognosis with targeted therapies. Conversely, this retrospective European Society for Blood and Marrow Transplantation registry study shows that young high cytogenetic risk responsive patients with human leukocyte antigen-matched donors have a high 8-year progression-free survival and low 2-year non-relapse mortality after allogeneic stem cell transplantation. This treatment then may compare favorably with targeted therapies for younger high cytogenetic risk patients.Background: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free sur…

MaleOncologyCancer ResearchTransplantation ConditioningBLOODCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatmentChronic lymphocytic leukemiaMedizinMULTICENTERKaplan-Meier EstimateHematopoietic stem cell transplantationTHERAPYchemistry.chemical_compound0302 clinical medicineHLA AntigensRisk FactorsIBRUTINIBeducation.field_of_studyHazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedPrognosisRELAPSED CLLTissue DonorsEUROPEAN-SOCIETY3. Good healthRisk factor analysisTreatment OutcomeOncology030220 oncology & carcinogenesisIbrutinibSURVIVALFemaleRefractory Chronic Lymphocytic LeukemiaAdultmedicine.medical_specialty3122 CancersPopulationHLA-matched donorMARROW TRANSPLANTATION03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterNon-relapse mortalityInternal medicinemedicineHumansTransplantation HomologouseducationAgedRetrospective StudiesChromosome Aberrationsbusiness.industryKinase- and BCL2 inhibitor refractorymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryTransplantationchemistryMATCHED UNRELATED DONORdel(17p)FOLLOW-UPbusiness030215 immunology
researchProduct

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of …

2006

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a mini…

MaleOncologymedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellHematopoietic stem cell transplantationCHOPDexamethasone0302 clinical medicineAutologous stem-cell transplantationGermanyhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularMelphalanEtoposideCytarabineHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell Mobilization3. Good healthSurvival RateTreatment OutcomeOncologyVincristine030220 oncology & carcinogenesisFemalemedicine.drugAdultmedicine.medical_specialtyVincristinePrednisolone03 medical and health sciencesInternal medicinemedicineHumansCyclophosphamideAgedChemotherapyMitoxantronebusiness.industrymedicine.diseaseCarmustineLeukemia Lymphocytic Chronic B-CellSurgeryDoxorubicinPrednisoneChlorambucilMantle cell lymphomaMitoxantronebusiness030215 immunologyAnnals of Oncology
researchProduct

Serological Survey of Rodent-Borne Viruses in Finnish Field Voles

2014

In northern Europe, rodent populations display cyclic density fluctuations, which can be correlated with the human incidence of zoonotic diseases they spread. During density peaks, field voles (Microtus agrestis) become one of the most abundant rodent species in northern Europe, yet little is known of the viruses they host. We screened 709 field voles, trapped from 14 sites over three years, for antibodies against four rodent-borne, potentially zoonotic viruses or virus groups: hantaviruses, lymphocytic choriomeningitis virus (LCMV), Ljungan virus (LV) and orthopoxviruses (OPV). Antibodies against all four viruses were detected. However, seroprevalence of hantaviruses, LV and LCMV was low. …

MaleOrthohantavirusviruksetHantavirus InfectionsCowpoxvirusesParechovirusOrthopoxvirusPoxviridae InfectionsLymphocytic ChoriomeningitisAntibodies ViralMicrobiologySeroepidemiologic StudiesZoonosesVirologymedicineAnimalsHumansLymphocytic choriomeningitis virusSeroprevalenceMicrotusFinlandHantavirusPicornaviridae InfectionsbiologyArvicolinaeIncidenceCowpox virusvirus diseasesOriginal Articlesbiology.organism_classificationmedicine.diseaseVirologyserological surveyInfectious DiseasesLjungan virusArvicolinaeParechovirusta1181FemaleSeasons
researchProduct

Determination of cytokeratins 1, 13 and 14 in oral lichen planus

2014

Cytokeratins (CK) are molecules of the cytoskeleton that contribute to the cellular differenciation. We studied the expression of CK1, CK13 and CK14 in thirty-three patients with OLP. The biopsied lesions were located in the dorsal surface of the tongue, the palatal keratinized mucosa and the nonkeratinized buccal mucosa. Objectives: This study aimed to determine the expression of CK1, CK13 and CK14 in oral lichen planus (OLP) and its relations with: clinical patterns, prognosis, drugs and tobacco intake and histopathological features. Study Design: Immunohistochemical analysis, retrospective, descriptive, observational and no randomized study. Results: No significant difference was observe…

MalePathologyMedicina ClínicaBasal (phylogenetics)//purl.org/becyt/ford/3.2 [https]Aged 80 and overMiddle Aged:CIENCIAS MÉDICAS [UNESCO]ImmunohistochemistryCiencias de la saludmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASORAL LICHEN PLANUS//purl.org/becyt/ford/3 [https]FemaleAdultmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDCK1CYTOKERATINOdontologíaBASAL CELL VACUOLIZATIONOdontología Medicina y Cirugía OralCytokeratinstomatognathic systemTongueOral and maxillofacial pathologymedicineHumansGeneral DentistryAgedRetrospective StudiesCK13Oral Medicine and Pathologybusiness.industryCK14ResearchKeratin-13Keratin-14medicine.diseaseOrthokeratosisEpitheliumLYMPHOCYTIC EXOCYTOSISstomatognathic diseasesOtorhinolaryngologyVacuolizationSurgeryOral lichen planusbusinessKeratin-1Lichen Planus Oral
researchProduct

Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF…

2021

Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) is usually straightforward, involving clinical, immunophenotypic (Matutes score), and (immuno)genetic analyses (to refine patient prognosis for treatment). CLL cases with atypical presentation (e.g., Matutes ≤ 3) are also encountered, and for these diseases, biology and prognostic impact are less clear. Here we report the genomic characterization of a case of atypical B-CLL in a 70-yr-old male patient; B-CLL cells showed a Matutes score of 3, chromosomal translocation t(14;18)(q32;q21) (BCL2/IGH), mutated IGHV, deletion 17p, and mutations in BCL2, NOTCH1 (subclonal), and TP53 (subclonal). Quite strikingly, a novel PAX5 mutation that w…

MaleProto-Oncogene Proteins B-rafChronic lymphocytic leukemiaCell Cycle ProteinsBiologymedicine.disease_causeSomatic evolution in cancerTranslocation GeneticEpigenesis Genetichematological neoplasmClonal Evolutionimmune system diseaseshemic and lymphatic diseasesExome SequencingmedicineHumansEpigeneticsReceptor Notch1neoplasmsLoss functionExome sequencingAgedHomeodomain ProteinsMutationPAX5 Transcription FactorGeneral Medicinemedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-CellProto-Oncogene Proteins c-bcl-2MutationCancer researchPAX5Tumor Suppressor Protein p53IGHV@Rapid Cancer CommunicationTranscription FactorsCold Spring Harbor Molecular Case Studies
researchProduct

Hepatitis B virus reactivation and alemtuzumab therapy

2005

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab the…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusHBsAgCD52Antibodies Neoplasmmedicine.medical_treatmenthepatitis B viruAntibodies Monoclonal Humanizedmedicine.disease_causeCampath-1HSettore MED/15 - Malattie Del SanguemedicineHumansAlemtuzumabImmunosuppression TherapyHepatitisHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface Antigensbusiness.industryacute hepatitiAntibodies Monoclonalvirus diseasesLamivudineImmunosuppressionHematologyGeneral MedicineMiddle AgedHepatitis BHepatitis Bmedicine.diseaseLeukemia Lymphocytic Chronic B-Celldigestive system diseasesLamivudineDNA ViralImmunologyReverse Transcriptase InhibitorsAlemtuzumabFemaleVirus Activationbusinesschronic lymphocytic leukaemiamedicine.drugEuropean Journal of Haematology
researchProduct